Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Definitions

• the present invention relates to organic complexes based on sitosterols, acylglycerols and strontium and their use in the pharmaceutical field and the dietetic industry. It also relates to methods for treating various diseases, in particular bone and blood diseases, by administration of these complexes. It also relates to pharmaceutical compositions containing these complexes, in particular for treating bone diseases, such as osteoporosis, and for treating hemopathies.
• Acylglycerols are present in most plants and are major constituents of vegetable and animal fatty substances. Only the number of fatty acids, their position on the glycerol, their chain length and the number of their possible unsaturations vary from one acylglycerol to another. They can be, in particular, mono-, di- or triacylglycerols. Sitosterol, of which there are two active isomers, ⁇ and ⁇ sitosterol, is also a constituent of all plants.
• hypoglycaemic such as, for example, the acacia extract (Egypt. J. Pharm. ScL, 1992, 33 (1-2), 327-340), or the teucrium oliverianum extract (Fitorick, 1984, 55 (4), 227-230). No link between the activity and the fraction containing the sterols is established.
• Osteoporosis is a disease characterized by low bone mass and deterioration of bone tissue, leading to bone fragility and thus an increased risk of bone fractures. Osteoporosis can affect the entire skeleton and causes fractures mainly in the hip, wrist or dorsal or lumbar spine. Osteoporosis is a major and global public health problem, increased by the Aging of the population. Also, although osteoporosis is often linked to people over the age of 50, this disease can happen at any age. Certain factors are linked to the development of osteoporosis or contribute to the probability of developing this disease, they are called risk factors.
• Amenorrhea low estrogen levels, low testosterone levels in men, anorexia, certain drug treatments (such as glucocorticoids, some anti-seizures), a diet low in calcium and vitamin D , smoking or excessive alcohol use are additional risk factors.
• a certain number of preventive or curative therapeutic treatments against osteoporosis are described or currently used, such as biphosphonates, calcitonin, hormonal treatments (estrogen and progestin), selective modulators of the estrogen receptor (raloxifene).
• strontium chloride Strontium chloride
• strontium ranelate Studies carried out with strontium chloride (strontium chloride) and with strontium ranelate have demonstrated a double action on cellular effectors of bone balance: stimulation of the multiplication of osteoblasts, and inhibition of the multiplication of osteoclasts.
• Therapeutic activity in animals requires high doses of strontium (200 mg strontium ranelate / day, corresponding to 68.2 mg of strontium metal) and is accompanied by a relatively large fixation of strontium in the bone. , with an elimination turnover which induces a toxic effect (osteomalacia lysis of the bone) from 800 mg / day of ranelate (4 times the active dose). This deleterious effect of fixing strontium in the bone is not considered below these doses as toxic because it does not alter the mechanical qualities of the bone.
• strontium can have harmful effects when the quantity fixed in the bone becomes too high, in particular during an impairment of renal function (Martine Cohen-Solal, Nephrol Dial Transplant ( 2002) 17 [Suppl. 2]: 30-34).
• the stimulation of the reproduction of osteoblates by strontium is therefore likely to induce stimulation of hematopoietic stem cells.
• the present invention therefore provides new organic complexes based on sitosterols, acylglycerols and strontium making it possible to increase the bioavailability of strontium.
• the authors of the present invention have in fact found that by administering to an animal particular organic complexes containing strontium, a growth bone is found, even at low doses of strontium, while exhibiting less fixation of strontium to the bone.
• the present invention therefore relates, according to a first aspect, to new organometallic complexes capable of being obtained by reaction of:
• -RI is an acyl residue of C14 to C24 fatty acid, saturated or not, linear or branched, a hydrogen atom, or a mono-, a di- or a tri-galactose or glucose
• -R2 is an acyl residue of C2 to Cl 8 fatty acid, linear or branched, saturated or not
• -R3 is an acyl residue of C14-C24 fatty acid, saturated or not, linear or branched, or a hydrogen atom.
• At least one of the groups RI or R3 of formula (I) above consists of an acyl residue of oleic acid (Cl 8: 1 [cis] -9).
• R2 has an unsaturation, preferably it is an acyl residue of fatty acid in Cl 8, advantageously it represents a residue of oleic acid or of one of its isomers of position of the double bond (cis -6, 7, 9, 11, 12 and 13) or one of its isoramified isomers.
• R2 represents an acetyl group.
• R3 of formula (I) above represents the hydrogen atom.
• the complexes of the invention are formed relatively easily by mixing the three types of constituents, generally keeping them at a temperature between 30 ° C. and 40 ° C for a dozen hours; the catalytic reaction for manufacturing the complex takes place more slowly at room temperature (5 to 8 days at 25 ° C); the complex is produced only slightly or not if the mixture is kept cold.
• the three types of compounds react very easily, by dissolving them in an organic solvent, for example dichloromethane, ether, chloroform, methanol, ethanol or ethyl acetate which will then be evaporated .
• organic solvent for example dichloromethane, ether, chloroform, methanol, ethanol or ethyl acetate which will then be evaporated .
• the cation of strontium which can be used to prepare the complexes according to the invention is therefore a divalent cation capable of complexing with the two types of organic derivatives above.
• strontium salts which can be used in the present invention to provide the strontium cation
• Mention may also be made of organic derivatives of strontium such as acetylacetonates, alcoholates, in particular strontium ranelate, or complexes of strontium with organic solvents, for example ethers, THF, DMF.
• organic strontium derivatives are generally soluble in organic solvents, more particularly in chlorinated solvents such as chloroform or dichloromethane.
• sitosterol used for the preparation of the complexes of the invention can be in ⁇ or ⁇ form. It is also possible to use a mixture of these two sterols.
• the product thus prepurified is subjected to 1 to 3 purification steps by high pressure liquid chromatography on a Cl 8 preparative column using eluent mixtures, such as methanol, in particular 100% methanol or mixtures of methanol and d acetonitrile, in particular 80-20 mixtures or any intermediate mixture making it possible to obtain sitosterol with a purity greater than 95 or even 99%.
• eluent mixtures such as methanol, in particular 100% methanol or mixtures of methanol and d acetonitrile, in particular 80-20 mixtures or any intermediate mixture making it possible to obtain sitosterol with a purity greater than 95 or even 99%. This purity is determined by gas chromatography.
• Sitosterol can also be prepared by extraction from plants using techniques described in the literature, for example P95 from the thesis presented in adjoin by Claude Cerdon, entitled: "Modulation of the production of steroidal sapogenins in response to inhibition sterol synthesis ”.
• This extraction is advantageously carried out by complexing the metals according to the process described in particular in French patent N °. 2,316,247 in which is described a method for isolating the 3-hydroxysteroids and the 3 oxostererodes from a mixture containing these compounds.
• plants or products of plant origin with a relatively high content of free sitosterol there may be mentioned in particular olive oil, soybean oil, cotton leaves, coffee leaves, wheat germs.
• the free sitosterol fraction contains a variable proportion depending on the plants of the 24 R and 24 S isomers, a proportion that is poorly known because little or not studied, and which seems to explain a better relative activity of the sterol fraction of certain plants and especially the excess sitosterol required when manufacturing new products.
• acylglycerols of formula (I) useful for the preparation of the complexes according to the invention can be isolated from most plants. More generally, the chemical fraction containing these products can be extracted from labiata, nettle (urtica dioica and urens), sage, bugles, alfalfa or alfalfa (medicago sativa), eucalyptus (globulus, delegatensis), angelica archangelica and angelica sinensis, umbelliferae, gymnema sylvestre (asclepiadaceae), marsdenia condurango, momordica charantia, gingko biloba, milk thistle, green tea, black tea (camellia sinensis), rhubarb, dioscorea dumetorum (dioscoreaceae), indigofera arrecta (papilionaceae), pittosporaceae, agrimonia eupatoria, turmeric xanth
• Unsaturated vegetable oils in particular first cold pressed olive oil, are used particularly advantageously as a source of acylglycerols.
• an oil or an oil fraction containing a high oleic acid content will be chosen as the source of acylglycerols useful according to the invention, such an oil generally containing a high proportion of acylglycerols useful according to the invention .
• oils examples include: - olive oil whose oleic acid content (Cl 8: 1) is between 60 and 80%, European oils being richer in Cl g: 1 than oils from North Africa,
• the fraction containing acylglycerols useful for preparing the complexes according to the invention can advantageously be prepared from olive oil in the following manner: a prepurification of the olive oil is carried out by passing it over a small height silica (10 to 15 cm), creating a vacuum and eluting with an organic solvent such as dichloromethane or a mixture of cyclohexane and ethyl acetate in proportions 96/4 or any other eluent having a similar polarity, so as to isolate the triglycerides present in the oil among which there is that having a Cl 8 on the C in position 2 of glycerol.
• an organic solvent such as dichloromethane or a mixture of cyclohexane and ethyl acetate in proportions 96/4 or any other eluent having a similar polarity
• the silica is then washed with ethyl acetate in order to recover the monoglycerides and diglycerides of interest according to the invention, that is to say those comprising a fatty acid Cl 8 on carbon in position 2 in the glycerol group.
• the fraction thus obtained is then passed through a silica column and eluted with different gradients of ethyl acetate / cyclohexane mixture between 10/90 and 100/0 so as to separate the different chemical families of the oil and to recover the active family sought.
• the acylglycerols used in the context of the present invention are chosen from 1,2-diolein and 1-oleoyl-2-acetyl glycerol.
• acylglycerols of the invention are also commercially available.
• l-oleoyl-2-acetylglycerol and 1,2-dioleoylglycerol are commercially available at a high purity level (more specifically, glycerol monooleate containing approximately 44% of dioleic glycerides, of which approximately 14% is the 1,2-diolein).
• glycerol monooleate containing approximately 44% of dioleic glycerides, of which approximately 14% is the 1,2-diolein.
• Such a compound is pharmaceutically accepted (European Pharmacopeia (4 Edition), USP 25 / NF20, and Japanese Standard of food Additives) and is notably marketed by the company Gattefossé under the name PECEOL®.
• equimolar proportions of the two lipid constituents are used; however, these conditions are not critical, and it is advantageous to use an excess of sitosterol relative to acylglycerol in proportions of 1 to 50 depending on the nature of the sterol (24 R or 24 S).
• the metal can be used in very low doses compared to the two other constituents, in particular in a ratio of 1/10 to 1/100 expressed in moles compared to acylglycerol.
• sitosterol gas chromatography, for racylglycerol HPLC with a light scattering detector, on a column of kromasil Cl 8, in the presence of an eluent consisting for example of isocratic acetonitrile.
• Gas chromatography can also be used to identify monoglycerides.
• the mass peak of the complex is generally not detectable with the usual methods, such as chemical ionization and electronic impact, which can be explained by the fact that the complexes formed by these two constituents with the metal are generally unstable like most organometallic complexes with biological activity.
• the invention relates to the use of the complexes described above as agents carrying strontium cations, the ligands linked to strontium serving to increase the bioavailability of said strontium.
• the complexes described above as agents carrying strontium cations
• the ligands linked to strontium serving to increase the bioavailability of said strontium.
• the organometallic complexes of strontium make it possible to obtain a bone growth activity at least equivalent to that of strontium dichloride at doses of strontium (expressed as metal) 10, or even 100 to 500 times lower than that used in the case of strontium dichloride.
• pharmacological activity is obtained with less fixation of strontium in the bone.
• strontium in the form of a complex is devoid of toxicity.
• organometallic complexes described in the present invention thus optimize the bioavailability of the transported strontium, allowing its therapeutic use with enhanced efficacy, low or zero toxicity, which has a considerable advantage over the state of the art.
• any excipient, vehicle or support well known to those skilled in the art can be used. Mention may be made, for example, and without limitation: lactose, corn starch, glucose, gum arabic, stearic acid or magnesium stearate, dextrin, mannitol, talc, oils of natural origin rich in essential unsaturated fatty acids and sterol.
• other additives well known to those skilled in the art can be used, such as stabilizers, desiccants, binders, pH buffers.
• compositions of the invention can be administered in various ways, in particular by the intramuscular, subcutaneous, sublingual, per os, permucosal, transdermal route (by administering the composition in the form of a patch or gel).
• the invention relates to the use of the complexes of the invention for the preparation of a medicament intended to be used as an agent regulating or stimulating bone growth, in particular in the treatment or prevention of bone growth deficits or dysfunctions, especially in the treatment or prevention of osteoporosis.
• the invention relates to the use of the complexes of the invention for the preparation of a medicament intended to be used to stimulate the production of hematopoietic stem cells, in particular in the treatment of blood pathologies s' accompanying a hematopoietic deficit, more specifically in addition to anticancer chemotherapy.
• the invention also relates to a method of treatment of the pathologies or disorders mentioned above, comprising the administration to a subject, in particular human, of an effective dose of a complex or of a pharmaceutical composition as defined above. .
• strontium ranelate can be administered to an animal in amounts which vary between about 200 and 1,800 mg / kg / day. In humans, the amount of strontium ranelate required to obtain therapeutic activity is 2 g / day.
• strontium is linked to the complex described in the invention necessary to obtain therapeutic activity are divided by 10 to 100, due to better bioavailability of the metal.
• treatment or “treat” include both curative and prophylactic treatments.
• the complex according to the invention can be used at an early stage of the disease, or before the appearance of the first symptoms, or even at an advanced stage of the disease.
• olive oil will be used, preferably oil of first cold pressing.
• Sitosterol will advantageously be introduced in the form of a plant extract.
• a commercial plant extract obtained from soybeans or tall oil can, in particular, use a commercial plant extract obtained from soybeans or tall oil.
• the dietetic product is obtained by simple mixing of the oil, plant extract rich in sitosterol and of the strontium cation, then heating and optionally stirring the mixture.
• mixtures consisting of: - 100 ml of oil, the fatty acids of which have a content of at least 60% in oleic acids, in particular olive oil,
• Example 2 Preparation of the complex according to the invention 1.70 g of commercial sitosterol dissolved in 10 ml of ethanol. 840 mg of strontium in the form of sulphate dissolved in 5 ml of purified water. 2 ml of a purified extract of mono and diglycerides extracted from palm-palm kernel oil (70 to 80% oleic acid). The mixture is stirred and heated for 30 minutes at 35 ° C. The ethanol is then evaporated.
• Example 3 Preparation of a pharmaceutical composition according to the invention A pharmaceutical composition is prepared from the complex formed according to Example 2. The product is introduced into gastro-resistant capsules. The product is then administered.
• Example 4 Preparation of a pharmaceutical composition according to the invention A pharmaceutical composition is prepared from the complex formed according to Example 1. The product is liquid and is in the form of an emulsion. It is ready to be administered orally in humans, or via the IP or rectal route in animals.
• Example 5 Preparation of an oro-dispersible pharmaceutical composition according to the invention A pharmaceutical composition is prepared from the complex formed according to Example 2 by adding to the mixture of excipients suitable for this pharmaceutical form.
• NP05 composition manufactured according to the invention, in which only the amount of strontium varies).
• Active Principle Strontium. Preparation: according to Example 4 Dosage of active principle: metal Strontium: (mg / kg / d) C 0 SrCl 68.2 NP05-F 68.2 NP05-f 12.15
• Administration volume 2 ml / kg.
• Route of administration Rectal route.
• Frequency of administration Once a day - every 24 hours. Duration of treatment: 21 days.
• Tissue samples - The femur bone is removed, cleaned of its tendon and muscle adhesions, then frozen after euthanasia of the animals.
• the bones are then subjected to a strontium assay by atomic absorption spectrometry.
• the diameter of the epiphysis of the femur is measured.
• the animals treated for only 3 weeks with the strontium prepared according to the invention had bone growth increased very significantly compared to the control animals and the batch treated with strontium dichloride.
• the activity was obtained with less fixation of strontium in the bone (x 2 for the lot with the same strontium dosage as the Sr dichloride lot, and x 1.5 for the lot six times less dosed in strontium).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Physical Education & Sports Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Plant Substances (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34508471

Family Applications (1)

Country Status (8)

Cited By (3)

Families Citing this family (4)

Citations (4)

• 2003
  • 2003-11-14 FR FR0313357A patent/FR2862224A1/fr active Pending
• 2004
  • 2004-11-15 WO PCT/FR2004/002912 patent/WO2005049038A1/fr active IP Right Grant
  • 2004-11-15 AT AT04805452T patent/ATE352308T1/de not_active IP Right Cessation
  • 2004-11-15 DE DE602004004559T patent/DE602004004559T2/de active Active
  • 2004-11-15 ES ES04805452T patent/ES2281026T3/es active Active
  • 2004-11-15 CA CA002545082A patent/CA2545082A1/fr not_active Abandoned
  • 2004-11-15 US US10/578,877 patent/US20070142306A1/en not_active Abandoned
  • 2004-11-15 EP EP04805452A patent/EP1682156B1/de not_active Not-in-force

Patent Citations (4)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events